AzTrials
AzTrials

Allergic RhinitisNCT02351830

Clinical Validation of Birch Pollen in the EEU

A study testing Birch Pollen and Nasal Brushing in people with Allergic Rhinitis, run by Queen's University at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The EEU has proven effective in multiple studies evaluating various aspects of seasonal allergic rhinitis. All previous EEU clinical trials have utilized ragweed or grass pollen as the allergen of choice for dispersal, due to the local population, but many emerging treatments for allergic rhinitis are allergen… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Allergic Rhinitis
What is being tested?
Birch Pollen and Nasal Brushing
Type of treatment
Surgery or procedure
How many people
59 participants
Where
1 siteCanada
Study dates
Jan 2015to Mar 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • minimum 2 year document history of rhinoconjunctivitis during typical tree pollen season (mid March to early May) OR completely non-atopic (allergic) to all environmental allergens.
  • positive skin test to birch allergen OR negative skin test to a panel of allergens at screening.

Who cannot join

  • participants with asthma.
  • participant is pregnant, lactating or actively trying to conceive.
  • participant is currently receiving allergen specific immunotherapy.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Kingston General Hospital

    Kingston, Ontario, K7L 2V7

Other trials in Canada

About this study

Official title: Controlled Birch Pollen Challenge in the Environmental Exposure Unit (EEU); Clinical Validation and Biomarker Exploration

The EEU has proven effective in multiple studies evaluating various aspects of seasonal allergic rhinitis. All previous EEU clinical trials have utilized ragweed or grass pollen as the allergen of choice for dispersal, due to the local population, but many emerging treatments for allergic rhinitis are allergen specific, thus it is desirable to expand the repertoire of pollen selection for use in the EEU. Ragweed, grass and birch pollen have differing appearances and sizes but essentially, both have characteristics which promote the ability to keep the pollen grains suspended and hence, the ability to maintain proper concentrations within the EEU. Preliminary validation studies conducted in the EEU, absent of human volunteers, have confirmed our ability to release, disperse and maintain birch pollen concentrations in the EEU using the existing technology.

This study aims to validate the use of birch pollen on a clinical scale. By adding non- allergic participants into the EEU, the investigators hope to determine if non-allergic persons exhibit differences at baseline in their "epigenetic biomarkers" from those who have pre-existing and established allergic airways inflammation.

Read the detailed description

The Environmental Exposure Unit (EEU) is a controlled allergen challenge model of allergic rhinitis ('hayfever') that has been used extensively to study various anti-allergic therapies. The EEU is a unique, internationally recognized research facility that allows for the exposure of groups of as few as 5 to as many as 150 volunteers simultaneously to ambient levels of airborne allergens such as ragweed pollen and provides a unique study environment ideally suited to evaluate efficacy and onset of action of various anti-allergic medications. This specialized facility, located within Kingston General Hospital, allows for the tight regulation of environmental variables such as air quality, temperature, humidity and CO2 levels as well as the precise maintenance of allergen concentration within this specialized room. Thus the EEU provides a closed environment in which participants are exposed to a predetermined, controlled, constant level of airborne pollen. All previous studies have used either ragweed or grass pollen, and the investigators have not clinically validated the use of birch pollen in the EEU. This study will confirm that the birch pollen circulated in the EEU can generate allergic rhinitis symptoms similar to those seen in the 'real world', and will also provide an opportunity to collect blood from participants before and after allergen challenge in order to better understand allergic inflammation, to hopefully someday identify novel therapies in allergic disease.

This study will consist of a Screening Visit and one pollen exposure visit. The duration of each participant's participation in the study from Screening to End of Study (EOS) will be approximately 3 weeks. The study population will consist of healthy, ambulatory male and female volunteers, 18-65 years of age with either a history of seasonal allergic rhinitis or a history of no allergic reactions. Approximately 55-75 participants will be screened to ensure 50 eligible participants are enrolled into the study (40 allergic, 10 non-allergic).

All participants will give written informed consent prior to any study procedures being performed. Participants who meet all inclusion/exclusion criteria during the screening process will be asked to return to the EEU for their pollen exposure visit. At the Screening visit participants will provide a full medical history and undergo a physical examination. They will have their height/weight and vitals measured and skin testing will be performed to confirm allergic response to a panel of common aeroallergens (or lack of response for the non-allergic individuals). Women of child bearing potential will undergo a urine pregnancy test to rule out pregnancy. Eligible participants will be asked to return to the research site for one 4 hour exposure to birch pollen in the Environmental Exposure Unit (EEU). Peripheral blood samples will be collected before and after pollen exposure for measurement of potential biomarkers.

Being tested
Birch Pollen, Nasal Brushing
Medical subject headings
Rhinitis, Allergic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Birch PollenOther

    Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.

  • Nasal BrushingProcedure or surgery

    To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Total Nasal Symptom Score from Baseline to each time point.

    Participants will assess their symptoms every 30 minutes during the 4-hour pollen exposure session and the sum of the 4 nasal symptoms (runny nose, stuffy nose, sneezing and itchy nose) which create the Total Nasal Symptom Score (TNSS)

    Measured: Second and Final Visit (4 hour pollen exposure)

Secondary outcomes (4)
  1. Percentage of people achieving a TNSS of 6 or greater

    The data will be evaluated to see how many participants achieved a TNSS of 6 or greater (out of a possible 12) at the second hour of pollen exposure. This is typically the time frame for qualification for randomization in a clinical trial.

    Measured: Second and Final Visit (4 hour pollen exposure)

  2. Percentage of people achieving a TRSS of 10 or greater

    The data will be evaluated to see how many participants achieved a TRSS of 10 or greater (out of a possible 24) during the second hour of pollen exposure.

    Measured: Second and Final Visit (4 hour pollen exposure)

  3. Change in Total Rhinoconjunctivitis Symptom Score from Baseline to each time point.

    Participants will assess their symptoms every 30 minutes during the 4-hour pollen exposure session and the sum of all of their symptoms (nasal symptoms listed above as well as itchy eyes, watery/tearing eyes, red burning eyes and itching of the ears/palate/throat) which create the Total Rhinoconjunctivitis Symptom Score (TRSS)

    Measured: Second and Final Visit (4 hour pollen exposure)

  4. Change in Peak Nasal Expiratory Flow (PNIF) from baseline at each time point.

    Participants will measure their nasal blockage using a Peak Nasal Inspiratory Flow meter every 30 minutes at the same time that they measure the rest of their symptoms. As the participant's nose become more congested this value should decrease.

    Measured: Second and Final Visit (4 hour pollen exposure)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2015 (estimated)
  2. Study startJan 2015
  3. Primary completionMar 2015
  4. Study completionMar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Enrolment
59 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02351830
Sponsor's protocol ID
Birch Validation Study
Status last verified
Apr 2015
First submitted
27 Jan 2015
Last updated
21 Apr 2015
Results posted
No
Data monitoring committee
No

Publications

  • Ellis AK, Soliman M, Steacy LM, Adams DE, Hobsbawn B, Walker TJ. Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU). Allergy Asthma Clin Immunol. 2016 Oct 19;12:53. doi: 10.1186/s13223-016-0156-7. eCollection 2016.

    PubMed 27777594

Questions about this trial

What is this clinical trial studying?

A study testing Birch Pollen and Nasal Brushing in people with Allergic Rhinitis, run by Queen's University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Total Nasal Symptom Score from Baseline to each time point. (time frame: Second and Final Visit (4 hour pollen exposure)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02351830, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in